IN THE SPOTLIGHT

Yvonne Diaz on the hopes and concerns of cancer patients regarding the use of AI wearables – Lung Cancer Europe

Yvonne Diaz on the hopes and concerns of cancer patients regarding the use of AI wearables – Lung Cancer Europe

Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

The quest for cancer cures is personal – ALK Positive

The quest for cancer cures is personal – ALK Positive

Signs of lung cancer in non-smokers people need to know

Signs of lung cancer in non-smokers people need to know

Ensacove Approved for ALK-Positive Locally Advanced or Metastatic NSCLC

Ensacove Approved for ALK-Positive Locally Advanced or Metastatic NSCLC

FDA Approves Ensacove

FDA Approves Ensacove

FDA Approves New Drug for Advanced Lung Cancer

FDA Approves New Drug for Advanced Lung Cancer

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

FDA approves ensartinib for metastatic non-small cell lung cancer

FDA approves ensartinib for metastatic non-small cell lung cancer

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Medscape Onsite: Riding the Wave of NSCLC Updates From San Diego

Advanced ALK-Rearranged NSCLC

Advanced ALK-Rearranged NSCLC

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Nuvalent boosts offering to $500M following promising NSCLC results

Nuvalent boosts offering to $500M following promising NSCLC results

NSCLC Biomarker Testing: Multidisciplinary Decisions and Timely Testing Are Key

NSCLC Biomarker Testing: Multidisciplinary Decisions and Timely Testing Are Key

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Role of Pulmonologists in Precision Medicine: Attitudes Towards Biomarker Testing for NSCLC

Role of Pulmonologists in Precision Medicine: Attitudes Towards Biomarker Testing for NSCLC

ALK-positive Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.

ALK-positive Non-Small Cell Lung Cancer Pipeline Drugs 2024 | Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC